Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Jan 15, 2020 (7 years ago)

Betamethasone Acetate/Betamethasone

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Assurance of Sterility

Cause type: Sterility / contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections. All sterility / contamination recalls.

What was recalled

BETAMETHASONE ACETATE/BETAMETHASONE (PF) Injectable Suspension, Betamethasone Acetate/Betamethasone (PF) CMC [2ML] 6MG/ML INJ SUSP, For IM, IA, IT Use, Shake Well. Preservative Free. Discard Unused Portion, 2 mL Single-use Vial, Rx only, Axia Pharmaceutical 1990 Westwood Blvd. Ste 135, Los Angeles, CA 90025; NDC 71283-0620-2

Affected NDC 71283-0620-02

Compare with the code on your package — it is the most precise check available.

Drug: Betamethasone

Recalling firm
Fusion IV Pharmaceuticals, Inc. dba Axia Pharmaceutical
NDC code
71283-0620-2
Origin
CA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0942-2020 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Betamethasone recalls

See all
Class II · Moderate risk

Betamethasone Dipropionate Ointment USP

CGMP Deviations: all products within expiry are being recalled because the manufacturing firm, Teligent Pharma, Inc.is discontinuing its stability study program.

Ongoing Stability / shelf life McKesson Corporation dba McKesson Drug Company NDC 63739-996-65 D-0850-2022
Class II · Moderate risk

Celestone Soluspan

cGMP deviations: Temperature abuse

Terminated Temperature excursion Mckesson Medical-Surgical Inc. Corporate Office NDC 0085-4320-01 D-1089-2022

Other recalls by Fusion IV Pharmaceuticals, Inc. dba Axia Pharmaceutical

All 2020 recalls
Class II · Moderate risk

Cholecalciferol

Lack of Assurance of Sterility

Terminated Sterility / contamination Fusion IV Pharmaceuticals, Inc. dba Axia Pharmaceutical NDC 71283-0251-3 D-0993-2020
Class II · Moderate risk

Cholecalciferol

Lack of Assurance of Sterility

Terminated Sterility / contamination Fusion IV Pharmaceuticals, Inc. dba Axia Pharmaceutical NDC 71283-0210-3 D-0992-2020